Why the study?
With the extensive use of tyrosine kinase inhibitors in hepatocellular cancer, cardiac adverse events have emerged in recent years.
What are the specific cardiac adverse events associated with different tyrosine kinase inhibitors in patients with hepatocellular cancer?
Population
4708 cardiac adverse event reports for sorafenib, regorafenib, lenvatinib, and cabozantinib in FAERS
Comparison
Sorafenib vs regorafenib vs lenvatinib vs cabozantinib
Design
Retrospective pharmacovigilance study using disproportionality and Bayesian analysis
Key result
Among 4,708 cardiac adverse event reports in hepatocellular cancer patients, lenvatinib was associated with the highest signal for cardiac failure (ROR 7.7; 95% CI 3.46-17.17).
Authors
Loading...
Lenvatinib cardiac signals merit vigilance in HCC; leaves open comparative TKI safety profiles for prospective study.
Observational (n=4,708)
What are the specific cardiac adverse events associated with different tyrosine kinase inhibitors in patients with hepatocellular cancer?
Odds Ratio: 7.7 (95% CI 3.46–17.17)
Different tyrosine kinase inhibitors used for hepatocellular cancer have distinct cardiac toxicity profiles, with lenvatinib showing strong signals for heart failure and acute coronary syndrome.
Lai et al. (2023) conducted an observational in Hepatocellular Cancer (n=4,708). Tyrosine kinase inhibitors (sorafenib, regorafenib, lenvatinib, cabozantinib) was evaluated on Cardiac failure (highest signal strength) (ROR 7.7, 95% CI 3.46-17.17). Among 4,708 cardiac adverse event reports in hepatocellular cancer patients, lenvatinib was associated with the highest signal for cardiac failure (ROR 7.7; 95% CI 3.46-17.17).